Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
REGN - Regeneron Pharmaceuticals, Inc.
Market Cap 80.32B P/E 19.87 EPS this Y 2.90% Ern Qtrly Grth 47.90%
Income 4.32B Forward P/E 17.49 EPS next Y 7.90% 50D Avg Chg -1.00%
Sales 13.49B PEG 2.21 EPS past 5Y 13.62% 200D Avg Chg -3.00%
Dividend N/A Price/Book 3.34 EPS next 5Y 10.50% 52W High Chg -13.00%
Recommedations 2.10 Quick Ratio 4.43 Shares Outstanding 108.42M 52W Low Chg 28.00%
Insider Own 1.53% ROA 7.62% Shares Float 103.45M Beta 0.12
Inst Own 89.78% ROE 16.55% Shares Shorted/Prior 1.98M/2.11M Price 732.12
Gross Margin 53.27% Profit Margin 32.04% Avg. Volume 638,883 Target Price 1,172.08
Oper. Margin 30.83% Earnings Date Oct 31 Volume 606,072 Change -0.94%
Healthcare | Biotechnology | United States
About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. News
11/19/24 Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
11/19/24 Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
11/18/24 FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
11/15/24 FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
11/15/24 Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
11/14/24 Citi initiates coverage on 5 new biotech stocks
11/14/24 2 Top Growth Stocks to Buy on the Dip
11/13/24 Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
11/13/24 Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
11/11/24 Regeneron Announces Investor Conference Presentations
11/10/24 We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease
11/07/24 Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer
11/07/24 EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
11/06/24 Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
11/06/24 Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
11/05/24 Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
11/02/24 Regeneron price target lowered to $1,126 from $1,137 at Truist
11/01/24 What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
11/01/24 Regeneron Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
11/01/24 Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
REGN Chatroom

User Image ntlaguy Posted - 24 minutes ago

Here are the top late-stage drugs in Regeneron’s Phase 3 pipeline, focusing on new drugs that have not been approved for any prior indications. This breakdown highlights their projected annual revenues and their potential impact on the company's future growth. 1. Nexiguran Ziclumeran (NTLA-2001) • Indications: Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN) • Target: TTR gene knockout using CRISPR/Cas9 • Details: The first in vivo CRISPR-based therapy offering a potentially curative one-time treatment for ATTR amyloidosis. • Projected Annual Revenue: $1 billion+ from ATTR-PN alone, with a multibillion-dollar market opportunityif successful in ATTR-CM, which affects a much larger population. Split 75% $NTLA and 25% $REGN 2. Itepekimab (in collaboration with Sanofi) • Indication: Chronic Obstructive Pulmonary Disease (COPD) • Target: IL-33 • Details: A monoclonal antibody targeting airway inflammation, aiming to address an unmet need in COPD treatment. • Projected Annual Revenue: Estimated at $1.5 billion, leveraging the significant COPD patient population and demand for new therapies. 3. Odronextamab • Indications: Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) • Target: CD20 and CD3 • Details: A bispecific antibody designed to engage T-cells to destroy B-cell malignancies. • Projected Annual Revenue: $800 million by 2035, addressing relapsed or refractory B-cell lymphomas. 4. Linvoseltamab • Indication: Multiple Myeloma • Target: BCMA and CD3 • Details: A bispecific antibody targeting myeloma cells, aiming to improve survival rates in patients with multiple myeloma. • Projected Annual Revenue: Estimated at $500 million, depending on market competition and uptake. 5. Fianlimab • Indications: First-line Metastatic Melanoma and Adjuvant Melanoma • Target: LAG-3 • Details: A monoclonal antibody offering an alternative checkpoint inhibition strategy to expand melanoma treatment options. • Projected Annual Revenue: Approximately $400 million, reflecting competition in the melanoma immunotherapy space. 6. Pozelimab (REGN3918) • Indications: Myasthenia Gravis, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (all in combination with Cemdisiran) • Target: C5 • Details: A monoclonal antibody addressing complement-mediated disorders in combination therapies. • Projected Annual Revenue: $300 million, with potential growth across multiple indications. 7. Garetosmab • Indication: Fibrodysplasia Ossificans Progressiva (FOP) • Target: Activin A • Details: A first-in-class therapy for a rare and debilitating genetic disorder with no current treatments. • Projected Annual Revenue: Estimated at $100 million, given the small FOP patient population. 8. REGN5713-5714-5715 • Indication: Birch Allergy • Target: Bet v 1 • Details: A monoclonal antibody combination for severe birch pollen allergies. • Projected Annual Revenue: Approximately $50 million, reflecting its niche market size.

User Image PencilNeckGeek Posted - 3 hours ago

$REGN good risk / reward here at this level imo

User Image ntlaguy Posted - 4 hours ago

$REGN $NTLA

User Image ntlaguy Posted - 4 hours ago

$REGN $NTLA This.

User Image diamondoptionsinc Posted - 5 hours ago

$REGN really might go full circle and trade at $700 again 😅

User Image jeffmeredith Posted - 7 hours ago

$REGN I check each day for a curl and the curl never comes. Any index deterioration and $700 comes fast. They really beat the crap out of this.

User Image LadyBoyStonks Posted - 7 hours ago

$REGN it closed already, which is why I bought it at $740, the open price that day, and why I went long today bc that gap down getting closed, it could get worse though, sept 7 2023, gap at 599, which is where it may head unfortunately, we shall see soon enough

User Image momobull Posted - 7 hours ago

$regn omg, I see it now. They want to close the 732 gap left open on Aug 2 2023.

User Image momobull Posted - 8 hours ago

$REGN unprecedented, I cannot find a comparable stock being buried coming off all time highs at this low of an RSI reading between 12-15 for 17 trading days. One idiot gave me meta and nflx, 🤡 not even speaking the same language.

User Image momobull Posted - 8 hours ago

$regn holy sheet, get your act together Stocktwits. Scared the f out of me

User Image Khanvict27 Posted - 8 hours ago

$REGN I have soo many cuts from trying to catch this knife. This shitty stock owes me $7k

User Image Whiskeyunderthebed Posted - 8 hours ago

$REGN this is a solid buy here. This has been getting accumulated for the last 10 trading days

User Image Sebast_Texas Posted - 8 hours ago

$REGN There had been lots of dark pool moves this week. In my opinion big whales covering already. Next week could reverse hard. Could run to test the sma10 around 775. My two cents. Unless Russia sents another interxontinental missile to Ukraine and market goes to shit.

User Image seet79 Posted - 8 hours ago

$REGN CEO needs to go - 50% haircut within a few months/-/

User Image momobull Posted - 10 hours ago

$regn 12-15 RSI since Nov1st. I've never seen it on a large cap like this for that long a period. NEVER!

User Image kenbkb Posted - 10 hours ago

$REGN I added 6 times on different days on the way down from 820. Never would have believed this would happen to such a revered co as REGN. I have to hearken back to a quote from Peter Lynch years ago... NEVER THINK A STOCK CANNOT GO LOWER, CAUSE IT CAN.

User Image momobull Posted - 10 hours ago

$REGN i said buckle up to go up not down. POS

User Image Fitz54 Posted - 10 hours ago

$REGN better hold the 52 week low or this is gonna be ugly

User Image shawnv069 Posted - 10 hours ago

$REGN puts?

User Image LadyBoyStonks Posted - 11 hours ago

$REGN they want every inch of it lmao Jesus😂

User Image LadyBoyStonks Posted - 11 hours ago

$REGN touch some grass bro or cash out, u clearly too over leveraged spam raging the board like this lol

User Image momobull Posted - 11 hours ago

$REGN I've never been so frustrated in my life with a reputable name. unbelievable, this garbage

User Image momobull Posted - 12 hours ago

$regn here we go, buckle up!

User Image momobull Posted - 12 hours ago

$REGN hot steaming garbage

User Image forprofit12 Posted - 14 hours ago

$REGN sorry not up to date on this one. What happened? This was always so promising?

User Image momobull Posted - 14 hours ago

$mrk and $mrna fully recovered from RFK drop. $regn this stinking poop still at dirt bottom.

User Image Fitz54 Posted - 14 hours ago

$REGN nope lol

User Image EthanJenkins1 Posted - 15 hours ago

$BMY $MRK $PFE $REGN $CKPT: Regarding CKPT ($3.50). I thought I would tag the other boards since this information will directly impact their share price. CKPT is obviously on the brink of a major FDA approval that could seriously cut into these other companies revenue, but according to ChatGPT, one of these companies will probably acquire CKPT very soon, in which case their shareholders should still know so they can have the opportunity to buy CKPT now before it happens.

User Image Fitz54 Posted - 15 hours ago

$REGN be great if this could find support at 750

User Image momobull Posted - 15 hours ago

$mrna huge runner. $pfe even this bouncing. $mrk also $regn pile of trash after getting clobbered 40% in 2.5 months. NOTHING

Analyst Ratings
RBC Capital Outperform Sep 24, 24
BMO Capital Outperform Sep 24, 24
Truist Securities Buy Sep 24, 24
Leerink Partners Market Perform Sep 24, 24
Wells Fargo Overweight Sep 23, 24
RBC Capital Outperform Sep 17, 24
Cantor Fitzgerald Neutral Sep 16, 24
Cantor Fitzgerald Neutral Sep 9, 24
RBC Capital Outperform Sep 9, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
STAHL NEIL EVP Research and Dev.. EVP Research and Development Feb 02 Option 399.66 30,750 12,289,545 82,769 02/06/24
Landry Robert E EVP Finance CFO EVP Finance CFO Feb 02 Option 378.98 400 151,592 23,974 02/06/24
McCourt Marion EVP Commercial EVP Commercial Feb 05 Sell 934.71 1,000 934,710 13,789 02/06/24
Bassler Bonnie L Director Director Jan 30 Sell 959 827 793,093 1,382 01/31/24
Bassler Bonnie L Director Director Jan 30 Option 380.95 827 315,046 2,209 01/31/24
Landry Robert E EVP Finance CFO EVP Finance CFO Jan 12 Option 378.98 800 303,184 23,406 01/17/24
RYAN ARTHUR F Director Director Nov 07 Sell 828.9 100 82,890 18,547 11/08/23
Bassler Bonnie L Director Director Aug 10 Sell 789 853 673,017 1,247 08/11/23
Bassler Bonnie L Director Director Aug 10 Option 391.92 853 334,308 2,100 08/11/23
McCourt Marion EVP Commercial EVP Commercial Aug 01 Sell 744.66 250 186,165 20,053 08/03/23
VAGELOS P ROY Director Director Feb 22 Option 270.43 42,500 11,493,275 366,583 02/24/23
Landry Robert E EVP Finance CFO EVP Finance CFO Oct 31 Sell 757.9 482 365,308 28,744 11/02/22
Landry Robert E EVP Finance CFO EVP Finance CFO Oct 31 Option 381.92 2,000 763,840 30,744 11/02/22
McCourt Marion EVP Commercial EVP Commercial Nov 01 Option 372.46 1,100 409,706 20,744 11/02/22
McCourt Marion EVP Commercial EVP Commercial Nov 01 Sell 750 1,100 825,000 19,644 11/02/22
Tessier-Lavigne Marc Director Director Sep 29 Option 413.33 10,838 4,479,671 5,881 10/03/22
Tessier-Lavigne Marc Director Director Sep 29 Sell 696.44 10,838 7,548,017 2,269 10/03/22
Bassler Bonnie L Director Director Sep 08 Option 386.84 3,167 1,225,122 1,691 09/12/22
Bassler Bonnie L Director Director Sep 08 Sell 711 3,167 2,251,737 1,082 09/12/22
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Sep 09 Option 270.43 30,000 8,112,900 41,580 09/12/22
RYAN ARTHUR F Director Director Aug 04 Option 412.58 10,453 4,312,699 21,092 08/08/22
RYAN ARTHUR F Director Director Aug 04 Sell 621.48 10,453 6,496,330 19,682 08/08/22
STAHL NEIL EVP Research and Dev.. EVP Research and Development Aug 04 Option 270.43 95,000 25,690,850 147,795 08/08/22
STAHL NEIL EVP Research and Dev.. EVP Research and Development Aug 04 Sell 613.95 23,782 14,600,959 52,795 08/08/22
RYAN ARTHUR F Director Director May 02 Sell 650.58 100 65,058 22,182 05/03/22
McCourt Marion EVP Commercial EVP Commercial May 02 Option 342.93 1,100 377,223 20,744 05/03/22
McCourt Marion EVP Commercial EVP Commercial May 02 Sell 656.97 1,100 722,667 19,644 05/03/22
Landry Robert E EVP Finance CFO EVP Finance CFO Apr 07 Option 393.75 9,500 3,740,625 32,158 04/11/22
Landry Robert E EVP Finance CFO EVP Finance CFO Apr 07 Sell 735.54 2,187 1,608,626 28,744 04/11/22
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Apr 07 Sell 721.1 5,114 3,687,705 16,900 04/11/22
Fenimore Christopher R. SVP Controller SVP Controller Apr 08 Option 413.05 7,450 3,077,222 30,066 04/11/22
Bassler Bonnie L Director Director Apr 07 Option 380.95 1,240 472,378 2,322 04/11/22
Bassler Bonnie L Director Director Apr 07 Sell 725 1,240 899,000 1,082 04/11/22
Landry Robert E EVP Finance CFO EVP Finance CFO Mar 28 Option 462.06 14,500 6,699,870 34,212 03/30/22
Landry Robert E EVP Finance CFO EVP Finance CFO Mar 28 Sell 688.04 2,683 1,846,011 28,744 03/30/22
Van Plew Daniel P EVP & General Mgr, I.. EVP & General Mgr, Industrial Feb 22 Option 399.66 40,000 15,986,400 70,578 02/24/22
Van Plew Daniel P EVP & General Mgr, I.. EVP & General Mgr, Industrial Feb 22 Sell 612.92 6,781 4,156,211 30,578 02/24/22
BROWN MICHAEL S Director Director Feb 23 Sell 608.68 500 304,340 7,162 02/24/22
MURPHY ANDREW J EVP Research EVP Research Feb 14 Option 179.13 10,000 1,791,300 68,470 02/16/22
MURPHY ANDREW J EVP Research EVP Research Feb 14 Sell 629.34 3,540 2,227,864 58,470 02/16/22
MURPHY ANDREW J EVP Research EVP Research Dec 08 Option 52.03 16,500 858,495 75,667 12/10/21
MURPHY ANDREW J EVP Research EVP Research Dec 08 Sell 664.97 7,122 4,735,916 59,167 12/10/21
Tessier-Lavigne Marc Director Director Dec 09 Option 371.4 3,784 1,405,378 5,862 12/10/21
Tessier-Lavigne Marc Director Director Dec 09 Sell 665 3,784 2,516,360 2,078 12/10/21
Landry Robert E EVP Finance CFO EVP Finance CFO Dec 08 Option 399.66 4,250 1,698,555 34,207 12/10/21
Landry Robert E EVP Finance CFO EVP Finance CFO Dec 08 Sell 664.66 781 519,099 29,957 12/10/21
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Dec 08 Option 179.13 30,000 5,373,900 46,520 12/10/21
SCHLEIFER LEONARD S President & CEO President & CEO Nov 19 Option 224.78 520,313 116,955,956 651,568 11/19/21
BROWN MICHAEL S Director Director Jan 27 Option 380.95 2,480 944,756 3,371 01/27/21
BROWN MICHAEL S Director Director Jan 27 Sell 554.32 2,480 1,374,714 891 01/27/21